Clinical Trials Directory

Trials / Terminated

TerminatedNCT06380166

Hepatitis C Lab Testing Comparison Study

Status
Terminated
Phase
Study type
Observational
Enrollment
1 (actual)
Sponsor
HealthPartners Institute · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hepatitis C (HCV) HCV antibody assays are the standard of care test used to screen for HCV, but confirmation of acute infection is relegated in the current US guidelines to polymerase chain reaction (PCR) which often takes multiple days and may result in a loss to follow up and treatment, especially in high prevalence populations. HCV core antigen is a new, research use only immunoassay intended for use on the Abbott Alinity i system, an FDA-cleared instrument for clinical chemistry and immunoassay testing. The aim of the study is to evaluate the 48-hour stability of HCV core antigen in fresh serum and plasma specimens collected from individuals with a detectable HCV viral load (HCL VL), as per a recent antibody assay test, under multiple specimen storage conditions mirroring those employed in clinical laboratories.

Detailed description

This study seeks to test the stability of a novel method of hepatitis-C testing called HCV core antigen testing. This will be accomplished by prospectively consenting patients who have had a recent, positive standard of care HCV viral load test, and drawing additional blood to conduct HCV core antigen testing within the infectious period. Viral load amount of the core antigen test will be recorded at baseline and subsequent timepoints. Stability is defined as \<10% change from baseline and will be recorded at various timepoints up to 144 hours post-draw. Stability will also be tested at room temperature vs. refrigerated storage and on the gel vs. off the gel processing techniques. This information is necessary to ensure HCV core antigen is sufficiently stable following specimen collection to enable robust, accurate, and precise measurement using the HCV core antigen assay.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTHepatitis C core antigenSemi-quantitative, automated immunoassay detecting core antigen of hepatitis C virus.

Timeline

Start date
2024-07-24
Primary completion
2024-08-20
Completion
2024-12-06
First posted
2024-04-23
Last updated
2025-01-06

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06380166. Inclusion in this directory is not an endorsement.